Sunday, December 09, 2018 8:09:02 PM
I found this:
First published March 8, 2018
“Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial”
Bruno Francois,1,2,3 Robin Jeannet,2 Thomas Daix,1,2 Andrew H. Walton,4 Matthew S. Shotwell,5 Jacqueline Unsinger,4 Guillaume Monneret,6,7 Thomas Rimmelé,7,8 Teresa Blood,4 Michel Morre,9 Anne Gregoire,9 Gail A. Mayo,10 Jane Blood,4 Scott K. Durum,11 Edward R. Sherwood,10,12 and Richard S. Hotchkiss4,13,14
FUNDING. Revimmune, NIH National Institute of General Medical Sciences GM44118.
Conflict of interest: M. Morre and A. Gregoire are Revimmune employees.
https://insight.jci.org/articles/view/98960#FN
Anne Grégoire
Director Process Development
Company Name Revimmune
Dates Employed Jun 2014 – Present
Employment Duration 4 yrs 7 mos
Location Paris Area, France
Interests- Following Companies: Toucan Capital, Northwest Biotherapeutics, Cognate Bioservices, ……
https://www.linkedin.com/in/anne-grégoire-86639b57/
Michel MORRE
Chief Science Officer chez REVIMMUNE
https://www.linkedin.com/in/michel-morre-7b6556153/?originalSubdomain=be
Interleukin 7 - Revimmune SAS
Alternative Names: CYT 107; Glycosylated recombinant human interleukin-7 - Cytheris; IL-7; Recombinant human interleukin-7 - Cytheris; rhIL-7; Second-generation CYT 99 007
Latest Information Update: 19 Sep 2018
https://adisinsight.springer.com/drugs/800020133
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM